Metformin-associated lactic acidosis in an elderly diabetic patient without classical risk factors: a case report [0.03%]
一例无典型危险因素的二甲双胍相关乳酸性酸中毒患者的病例报告
Yali Zheng,Jia Sun,Peng Zhang et al.
Yali Zheng et al.
Metformin is a cornerstone medication and first-line therapy for type 2 diabetes mellitus (T2DM), with a well-established safety profile and widespread use over many years. Its most common adverse effects are gastrointestinal in nature. How...
The magnitude of drug-related problems, typology, and predictors among patients admitted to the pediatric intensive care unit: impact of pharmacist-led interventions in Northwest Ethiopia [0.03%]
药师主导干预在埃塞俄比亚西北部儿科重症监护病房患者中的药物相关问题的影响：药物相关问题的规模、类型和预测因素
Abel Temeche Kassaw,Getachew Yitayew Tarekegn,Tigabu Eskeziya Zerihun et al.
Abel Temeche Kassaw et al.
Background: Drug-related problems (DRPs) are a significant concern in hospitalized patients. In Ethiopia, DRPs occur at a rate of 9.2 per 100 admissions and 9.4 per 1,000 patient days; however, pediatric-specific data are...
Disparities and trends in drug-related adverse reaction mortality in the United States, 1999-2020 [0.03%]
1999至2020年美国药物不良反应死亡率的差异及趋势
Liwei Guo,Xiuxun Dong
Liwei Guo
Background: Adverse drug reactions (ADRs) are a leading cause of morbidity and mortality worldwide. Despite advances in pharmacovigilance, population-level evidence on long-term trends and disparities in ADR-related morta...
Donor and recipient genetic polymorphisms modulate tacrolimus pharmacokinetics during voriconazole co-therapy: a drug-drug interaction study in liver transplant recipients [0.03%]
供体和受体的基因多态性调节伏立康唑联合他克莫司治疗时的他克莫司药代动力学：肝移植受者的药物相互作用研究
Jieling Li,Liubing Li,Yanzhe Xia et al.
Jieling Li et al.
Background: While recipient cytochrome P450 (CYP) genetic polymorphisms are established modulators of tacrolimus (TAC) pharmacokinetics, the combined effects of donor-derived hepatic and recipient intestinal CYP3A4/5 and ...
Andrew Bate,Philip Michael Tregunno
Andrew Bate
Challenges and future perspectives of enhanced passive safety surveillance of influenza vaccines in Europe [0.03%]
欧洲流感疫苗增强型被动安全监测的挑战与未来展望
Marina Amaral de Avila Machado,Sonja Gandhi-Banga,Laurence Serradell et al.
Marina Amaral de Avila Machado et al.
Postmarketing surveillance is critical for confirming the safety profile of vaccines following regulatory approval. This article contributes to the ongoing discussion on safety surveillance strategies for seasonal influenza vaccines in Euro...
Evaluating the patterns of use and safety of lenalidomide treatment in myelodysplastic syndromes: a European, observational multi-registry study [0.03%]
来那度胺治疗骨髓增生异常综合征的使用模式和安全性评价：一项欧洲、观察性多注册表研究
Iris Kim,Aidan Makwana,Victoria Ezenma et al.
Iris Kim et al.
Background: Lenalidomide is an immunomodulatory agent thought to inhibit the growth of del(5q) haematopoietic progenitors in myelodysplastic syndromes (MDS) that was approved for use in Europe for certain forms of these c...
Drug-induced intestinal obstruction: insights from the FDA Adverse Event Reporting System [0.03%]
药物性肠梗阻：来自美国食品药品监督管理局不良事件数据库的见解
He Li,Yingjie Li,Lu Liu et al.
He Li et al.
Background: Intestinal obstruction is a severe abdominal condition that can be triggered by various medications; however, the drugs most strongly and frequently linked to this adverse event (AE) remain insufficiently defi...
Prevalence and predictors of prescribing errors in a primary care setting in Ghana [0.03%]
加纳初级卫生保健机构处方错误的流行率及其预测因素
Richard Delali Agbeko Djochie,Jonathan Boakye-Yiadom,Adwoa Oforiwaa Kwakye et al.
Richard Delali Agbeko Djochie et al.
Background: Prescribing errors are a significant cause of preventable harm in healthcare, particularly in low- and middle-income countries where system-level safeguards are often lacking. However, data on their prevalence...
Integration of pre‑existing cardiovascular comorbidity into CDK4/6 inhibitor selection for breast cancer [0.03%]
合并存在的心血管共病情况以选择乳腺癌的CDK4/6抑制剂治疗
Chanhyun Park,Kiyoung Kim,Nora B Abifaraj et al.
Chanhyun Park et al.
Background: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors differ in cardiovascular (CV) safety. Ribociclib has been associated with a higher risk of CV adverse events compared to palbociclib and abemaciclib. ...